Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 8Phase 1/2 4Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Sarcoma 1Gynecologic 1Breast 1

Conditions

Glioblastoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Gliosarcoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × pamiparib × Clear all
NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

BeiGene

Phase 1/2 Completed
116 enrolled 31 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

BeiGene

Phase 1/2 Completed
128 enrolled 36 charts
Breast

Triple Negative Breast Neoplasms

NCT03914742 2025-01-14

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
67 enrolled 18 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡